We performed a high-resolution analysis of the biological characteristics of plasma DNA in systemic lupus erythematosus (SLE) patients using massively parallel genomic and methylomic sequencing. A number of plasma DNA abnormalities were found. First, aberrations in measured genomic representations (MGRs) were identified in the plasma DNA of SLE patients. The extent of the aberrations in MGRs correlated with anti-double-stranded DNA (anti-dsDNA) antibody level. Second, the plasma DNA of active SLE patients exhibited skewed molecular size-distribution profiles with a significantly increased proportion of short DNA fragments. The extent of plasma DNA shortening in SLE patients correlated with the SLE disease activity index (SLEDAI) and antidsDNA antibody level. Third, the plasma DNA of active SLE patients showed decreased methylation densities. The extent of hypomethylation correlated with SLEDAI and anti-dsDNA antibody level. To explore the impact of anti-dsDNA antibody on plasma DNA in SLE, a column-based protein G capture approach was used to fractionate the IgG-bound and non-IgG-bound DNA in plasma. Compared with healthy individuals, SLE patients had higher concentrations of IgG-bound DNA in plasma. More IgG binding occurs at genomic locations showing increased MGRs. Furthermore, the IgG-bound plasma DNA was shorter in size and more hypomethylated than the non-IgG-bound plasma DNA. These observations have enhanced our understanding of the spectrum of plasma DNA aberrations in SLE and may provide new molecular markers for SLE. Our results also suggest that caution should be exercised when interpreting plasma DNA-based noninvasive prenatal testing and cancer testing conducted for SLE patients.
We performed a high-resolution analysis of the biological characteristics of plasma DNA in systemic lupus erythematosus (SLE) patients using massively parallel genomic and methylomic sequencing. A number of plasma DNA abnormalities were found. First, aberrations in measured genomic representations (MGRs) were identified in the plasma DNA of SLE patients. The extent of the aberrations in MGRs correlated with anti-double-stranded DNA (anti-dsDNA) antibody level. Second, the plasma DNA of active SLE patients exhibited skewed molecular size-distribution profiles with a significantly increased proportion of short DNA fragments. The extent of plasma DNA shortening in SLE patients correlated with the SLE disease activity index (SLEDAI) and antidsDNA antibody level. Third, the plasma DNA of active SLE patients showed decreased methylation densities. The extent of hypomethylation correlated with SLEDAI and anti-dsDNA antibody level. To explore the impact of anti-dsDNA antibody on plasma DNA in SLE, a column-based protein G capture approach was used to fractionate the IgG-bound and non-IgG-bound DNA in plasma. Compared with healthy individuals, SLE patients had higher concentrations of IgG-bound DNA in plasma. More IgG binding occurs at genomic locations showing increased MGRs. Furthermore, the IgG-bound plasma DNA was shorter in size and more hypomethylated than the non-IgG-bound plasma DNA. These observations have enhanced our understanding of the spectrum of plasma DNA aberrations in SLE and may provide new molecular markers for SLE. Our results also suggest that caution should be exercised when interpreting plasma DNA-based noninvasive prenatal testing and cancer testing conducted for SLE patients.
genomic representation | size profiling | epigenetics | massively parallel sequencing | autoimmune disease S ystemic lupus erythematosus (SLE) is a prototype autoimmune disease that has the potential of affecting multiple organ systems, including the skin, muscles, bones, lungs, kidneys, as well as the cardiovascular and central nervous systems (1, 2) . SLE can cause various tissue inflammation and damages in a chronic manner. Renal complications, infections, myocardial infarctions, and central nervous system involvement are the major causes of death in SLE patients (3). The extremely variable clinical manifestations and the absence of effective tests to monitor disease activity present a challenge for clinical management (2, 3) .
The etiology of SLE remains unknown and is multifactorial, involving genetic, epigenetic, environmental, hormonal, and immunologic factors (2, 4) . Cell death has been regarded as an important event in the pathogenesis of SLE, as it leads to the release of antigens, such as nucleic acids, for immune complex formation, which may trigger a cascade of immune responses against the bodily tissues of the SLE patients (5, 6) . Defects in the mechanism of cell death (7) , impairment in the clearance of dead cells (8) , and deficiency in DNase activity (9) have been implicated in SLE and suggested to be involved in the generation of autoantigens (5, 6) .
In addition, epigenetic regulation is an important mechanism for maintaining the normal functioning of the immune system. Perturbation of the epigenetic regulation can disrupt the immunologic self-tolerance (10) . Following the demonstration of impaired DNA methylation of T cells in SLE patients (11) , an increasing amount of evidence has highlighted the contribution of epigenetic mechanisms in this disorder (12, 13) . Hypomethylated apoptotic DNA from cells has been shown to be potentially pathogenic and may provoke the humoral and cellular immune responses in SLE (14) .
SLE was one of the pathological conditions reported to be associated with the presence of circulating DNA nearly 50 years ago (15) . Since then, studies using various detection methods have demonstrated the elevations of circulating DNA in SLE patients (16, 17) . In addition, early reports have highlighted that
Significance
Through the use of massively parallel sequencing, we have demonstrated a spectrum of plasma DNA abnormalities in patients with systemic lupus erythematosus. These abnormalities include aberrant measured genomic representations, hypomethylation, and DNA fragment size shortening. The binding of anti-double-stranded DNA antibody to plasma DNA appears to be an important factor associated with these abnormalities. These findings provide valuable insights into the biology of plasma DNA in an autoimmune disease and have potential implications for the development of new molecular markers for systemic lupus erythematosus.
the circulating DNA that form immune complexes with autoantibodies in SLE patients displays a characteristic fragmentation pattern that resembles the DNA laddering pattern of apoptosis by gel electrophoresis (18) . These findings have suggested an interplay of apoptosis and circulating DNA in the pathogenesis of SLE. However, there have been very few studies reporting the detailed biological characterization of circulating DNA in SLE.
The advent of massively parallel sequencing has enabled the investigation of circulating DNA at single-base resolution on a genome-wide scale in fields such as noninvasive prenatal testing (19) (20) (21) and cancer detection (22) (23) (24) (25) . It would be of great interest to use this technology to explore the genomic and methylomic features of plasma DNA in SLE patients. In particular, the interplay of deregulated cell death, altered epigenetic regulation and production of autoimmune antibodies in SLE patients might cause abnormal patterns of circulating DNA. Hence, in this study we delineated the biological characteristics of DNA in the plasma of SLE patients using genome-wide genomic and methylomic sequencing. Fig. 1 . Circos plots showing the genomic distributions of plasma DNA for a representative case in each of the control, inactive SLE, and active SLE groups. From inside to outside, the rings show data from a representative healthy individual (C005), inactive SLE patient (S011), active SLE patient (S112), and ideograms of the human chromosomes, respectively. Each dot represents a 1-Mb bin. The green, red, and gray dots represent bins with significant increased, decreased, and normal MGRs, respectively. The distance between intervals represents a z-score difference of 5.
Results
Genomic Representations of Plasma DNA in SLE Patients. First, we assessed if the plasma DNA molecules in the circulation of SLE patients were evenly distributed across the genome. Plasma DNA from 24 SLE patients and 11 healthy individuals were analyzed by paired-end massively parallel sequencing. SLE patients were divided into active and inactive groups according to their SLE disease activity index (SLEDAI), which is a clinical index for the measurement of disease activity (26) . Fifteen patients with SLEDAI below or equal to 6 (median: 4, range: 0-6) were classified as the inactive group, and nine patients with SLEDAI over 6 (median: 8, range: 7-16) were classified as the active group. A median of 120 million (range: 18-208 million) alignable and nonduplicated paired-end reads were obtained for the plasma DNA per case for subsequent analyses (Dataset S1).
We assessed the genomic distribution of plasma DNA across segments (bins) of the human genome, each of 1 Mb in size. The number of sequence reads in each bin was tallied and adjusted by GC-correction as previously described (25) . The control group consisted of 11 healthy individuals and this group showed even genomic distribution of the plasma DNA molecules as reported previously [ Fig. 1 , the innermost ring of the circos plot (27) ]. To determine if the plasma DNA profiles of SLE patients showed differences in genomic representation, we compared the number of plasma DNA sequences aligned to a bin to the mean number detected among the control group for the same bin. We expressed the difference as a z-score, which was the number of SDs away from the mean of the control group. Bins with z-scores below −3 and above +3 were considered as showing significant under-and over-representation, respectively. We termed these changes aberrant measured genomic representations (MGRs).
The percentages of bins with aberrant MGRs among the healthy individuals, inactive and active SLE patients are shown in Fig. 2A . We tested for aberrant MGRs in the plasma of each healthy individual by comparing against the genomic distributions of the remaining control group. None of the healthy individuals exhibited any bin with aberrant MGRs in plasma (percentage of bins with aberrant MGRs = 0%). The percentages of bins with aberrant MGRs were higher among the SLE patients (active group: median 8.1%, range 1.1-52%; inactive group: median 6.5%, range 0.5-32.1%) compared with the controls (P < 0.0001, Kruskal-Wallis test) ( Table 1 ). The MGR patterns of one representative case in each of the control, inactive SLE, and active SLE groups are shown in Fig. 1 . Correlation analyses were performed between the percentage of bins with aberrant MGRs in SLE patients with the serum antidouble-stranded DNA (anti-dsDNA) antibody levels (r = 0.604, P = 0.0018, Spearman's correlation), and SLEDAI (r = 0.226, P = 0.29, Spearman's correlation). Size Analysis of Plasma DNA in SLE Patients. The sizes of plasma DNA molecules in the samples discussed in the previous section were deduced from the start and end coordinates of the pairedend reads (28) . The size-distribution profiles of one healthy individual, one active, and one inactive SLE patient are shown in Fig. 3 . The size distribution of plasma DNA in healthy individuals showed a major peak at 166 bp and a series of smaller peaks occurring at a 10-bp periodicity (Fig. 3) . The size-distribution profiles of the SLE patients were different. The height of the 166-bp peak was reduced, whereas the other peaks for DNA fragments in smaller sizes, particularly those shorter than 115 bp, were elevated. These changes were more pronounced in the active SLE group than the inactive SLE group.
To systematically compare the size profiles between all samples, we defined a plasma DNA molecule ≤ 115 bp in size as a short DNA fragment and determined the percentage of short plasma DNA molecules in each sample. The data are shown in Fig. 2B . The median percentages of short plasma DNA fragments in the plasma of healthy individuals, inactive SLE and active SLE patients were 10% (range: 8-15%), 14% (range: 8-36%), and 31% (range: 11-84%), respectively. Positive correlations were observed between the percentage of short DNA fragments and SLEDAI (r = 0.532, P = 0.0076, Spearman's correlation) and the anti-dsDNA antibody level (r = 0.758, P < 0.0001, Spearman's correlation).
Methylation Status of DNA in Plasma of SLE Patients. Another sample set consisting of 24 SLE patients and 10 healthy individuals were subjected to methylation analysis. For the SLE patients, four inactive (S006, S013, S017, and S019) and four active cases (S004, S005, S010, and S015) had been studied in the above-mentioned MGR and size analyses, as sufficient volume of plasma could be harvested from these cases for both genomic and methylomic sequencing. For those with insufficient volume of plasma for both types of analysis, either genomic or methylomic analysis was performed on each sample. Plasma DNA was bisulfite-converted and analyzed by paired-end massively parallel sequencing, as previously described (29) . A median of 125 million (range: 26-191 million) alignable and nonduplicated reads were obtained per case for subsequent analysis. Among the 24 SLE cases, 11 were in the inactive SLE group (SLEDAI median: 3, range: 0-5) and 13 were in the active SLE group (SLEDAI median: 8, range: 7-18).
The genome-wide methylation density of plasma DNA for each case refers to the proportion of CpG sites deemed to be (Fig. S1 ).
Next we analyzed the methylation densities of each 1-Mb bin across the genome. For every bin, the plasma DNA methylation densities of the SLE patients were compared with the mean methylation density obtained from the 10 healthy individuals of the corresponding bin. Bins with methylation densities that were more than 3 SDs lower or higher than the mean of the control group, namely with z-scores below −3 or above +3, were deemed as significantly hypo-and hypermethylated, respectively (24) . The percentages of bins with significant hypomethylation among the healthy individuals, inactive and active SLE patients are shown in Fig. 2C . Patients in the active group showed more hypomethylated bins (median: 42.7%, range: 1-94.7%) than the inactive group (median: 1.2%, range: 0-22%) ( Table 2 ). The methylation patterns of one healthy individual, one active, and one inactive SLE patients are shown in Fig. 4 . The percentage of hypomethylated bins correlated with SLEDAI (r = 0.653, P = 0.0005, Spearman's correlation) and anti-dsDNA antibody levels (r = 0.555, P = 0.0059, Spearman's correlation) of the SLE patients.
We reported in a previous study that shorter plasma DNA fragments tend to be more hypomethylated (29) . Here we explored if a similar relationship is present in the plasma of SLE patients. First, the genome-wide methylation density was inversely correlated with the proportion of short DNA (≤115 bp) in all individuals (r = −0.550, P = 0.0007, Spearman's correlation) (Fig. S2) . Next, we determined the methylation densities of DNA fragments of different sizes ranging from 20 to 250 bp, using sequence reads that covered at least 1 CpG site (29) (Fig.  S3) . For fragments between 40 and 180 bp, which accounted for the majority of plasma DNA molecules, the same trend as previously reported for the plasma of pregnant women was observed (29) . It is noteworthy that the active SLE group showed greater reductions in methylation densities with progressive shortening of the plasma DNA fragments compared with the healthy individuals and patients in the inactive SLE group (Fig. S3) .
Effects of IgG Binding on Plasma DNA of SLE Patients. Autoantibodies have a direct contribution to the pathogenesis of SLE (2, 3) and are responsible for many of the clinical manifestations (30) . One of such autoantibodies is the anti-dsDNA antibody, which can bind to the DNA in plasma (31) . Studies have reported that IgGclass anti-dsDNA antibody has high avidity for dsDNA and is implicated in the pathogenesis of SLE (31, 32) . We hypothesized that the binding of anti-dsDNA antibody to plasma DNA might alter the stability or clearance of DNA in plasma and might result in observable aberrations in genomic representation, size, or methylation profiles of plasma DNA. To study the effect of anti-dsDNA antibody binding on plasma DNA, two sample sets were recruited: one for genomic representation and size analysis and the other for methylation level analysis. Each sample set included two healthy individuals, two inactive SLE patients, and two active SLE patients. For each case, the plasma sample was divided into two portions. One portion was not subjected to any treatment and was termed the neat fraction. The other portion was incubated with protein G and subjected to column capture. Protein G binds human IgG, including anti-dsDNA antibody. Therefore, column-based protein G capture further allowed the plasma sample to be separated into IgG-bound and non-IgG-bound fractions. The genomic representation, molecular size, and methylation profiles were compared among the neat, IgG-bound and non-IgG-bound DNA fractions. Higher concentrations of IgG-bound DNA were found in the plasma of SLE patients (median: 494.5 copies/mL, range: 92-983 copies/mL), compared with the healthy individuals (median: 68.5 copies/mL, range: 41-139 copies/mL) ( Table 3) .
For genomic representation analysis, the z-score for each 1-Mb bin was calculated in the neat, IgG-bound, and non-IgG-bound fractions. Next, we calculated the z-score difference between the IgG-bound and non-IgG-bound fractions for each bin, expressed as the "IgG binding index." The IgG binding index of each bin was then compared with the z-score of MGR in the neat fraction for the corresponding bin (Fig. 5) . We hypothesized that a higher proportion of plasma DNA fragments originating from regions showing increased MGRs were bound by anti-dsDNA antibody and would be found in the IgG-bound fraction. Hence, the IgG binding index for such locations should be higher. For regions exhibiting decreased MGRs, the reverse would be true and the IgG binding index should be more negative. Indeed, for SLE cases with high anti-dsDNA antibody levels (S081, S082, S112), the z-scores of bins with aberrant MGRs in the neat fractions showed a positive relationship with the corresponding IgG binding index (r = 0.31, P < 0.0001, Pearson's correlation) (Fig. 5) .
For the size analysis, the SLE case (S073) with SLEDAI 0 and negative anti-dsDNA antibody showed similar plasma DNA sizedistribution profiles in the neat, IgG-bound, and non-IgG-bound Fig. 4 . Plasma methylation profile analysis for a representative case in each of the control, inactive SLE, and active SLE groups. From inside to outside, the rings showed data from a representative healthy individual (C040), inactive SLE patient (S124), active SLE patient (S027), and ideograms of the human chromosomes, respectively. Each dot shows the methylation density for a 1-Mb bin. The green, red, and gray dots represent bins with significant hypermethylation, hypomethylation, and normal methylation, respectively. The distance between intervals represents a z-score difference of 5.
fractions to the two healthy individuals (Fig. S4 A-C) . In contrast, for three SLE patients (S081, S082, and S112) with high anti-dsDNA antibody levels and SLEDAI ≥ 6, the size-distribution profiles demonstrated a shortening of plasma DNA in each of the neat, IgG-bound, and non-IgG-bound fractions ( Fig.  6 and Fig. S4 D and E) . The IgG-bound fractions of these three SLE patients showed an enrichment of short DNA fragments ≤115 bp compared with the non-IgG-bound fractions (Fig. S5) .
For the methylation analysis, compared with the two healthy individuals, SLE patients had lower genome-wide methylation densities in each of the neat, IgG-bound, and non-IgG-bound fractions (Table 4) . For the two active SLE patients with high anti-dsDNA antibody levels (S147 and S203), the IgG-bound fractions showed the lowest genome-wide methylation densities and the highest number of hypomethylated bins. Correspondingly, the non-IgG-bound fractions had the highest genome-wide methylation densities and lowest number of hypomethylated bins (Table 4) . Among these two SLE cases, the percentages of hypomethylated bins decreased in the following order: IgG-bound, neat, and non-IgG-bound fractions (Fig. 7) . On the other hand, for the two SLE cases with low anti-dsDNA antibody levels (S124, 125), the genome-wide methylation densities and number of hypomethylated bins were similar between the IgG-bound and nonIgG-bound fractions (Table 4) .
Discussion
In this study, we investigated the characteristics of plasma DNA of SLE patients in a high-resolution and genome-wide manner with the use of paired-end massively parallel sequencing. In general, the higher the disease activity, the greater the extent and the wider the range of plasma DNA aberrations were observed. Plasma DNA of SLE patients showed aberrant MGRs, size shortening, and hypomethylation. We further obtained evidence that suggested that those plasma DNA aberrations were at least in part related to DNA binding by IgG class antibodies, for example anti-dsDNA antibodies. These observations are particularly interesting because they suggest that a blood constituent, namely anti-dsDNA antibody, could alter the molecular characteristics and profile of plasma DNA.
We showed that the genomic representations of plasma DNA in SLE patients were different from those of healthy controls. The percentages of bins showing aberrant MGRs correlated with the anti-dsDNA antibody level but not the SLEDAI. We therefore hypothesized that antibody binding of plasma DNA may be related to the observed aberrant MGRs. In the IgG binding experiments, we indeed showed that more plasma DNA molecules originating from the regions with increased MGRs were associated with the IgG binding. Perhaps the binding of anti-dsDNA antibody to plasma DNA would protect the bound DNA from enzymatic degradation, or would impair the clearance mechanism, such as the phagocytic system (33) (34) (35) . Studies have also reported the preferential binding of anti-DNA antibody to particular DNA sequences, for example, DNA fragments containing certain CpG motifs (36, 37) . The retention of antibody-bound DNA might therefore enhance the genomic representation in regions with preference for antibody binding, whereas regions with less antibody binding preference would be underrepresented. These changes might then be detected as increased MGRs and decreased MGRs, respectively. Currently, a number of noninvasive prenatal tests for fetal aneuploidy screening are based on the detection of copy number aberrations in maternal plasma DNA (19, 21, 38) . Therefore, caution should be taken when applying such tests to pregnancies with underlying SLE, as the aberrant MGRs might reflect the activity of SLE, rather than the genomic aberrations originating from the fetus. Similarly, as plasma DNA sequencing for copynumber aberrations (23, 25) and hypomethylation (24) has been reported for cancer detection, one should also be wary of the possibility of false-positive results for patients with SLE.
In terms of size analysis, plasma of SLE patients showed an increased proportion of short DNA fragments. The proportion of short DNA fragments (≤115 bp) in the plasma of the active SLE patients was threefold higher than that of healthy individuals and could contribute up to 84% of the total DNA in plasma. Hence, when plasma DNA size analysis is used for noninvasive prenatal testing (39) in pregnant subjects with SLE, the possibility of false-positive results because of the underlying SLE should be borne in mind.
The shortening of plasma DNA in SLE patients may be a result of the increased production or decreased clearance of short DNA fragments. Our data show that the shortening of plasma DNA was positively correlated with the disease activity of the SLE patients and the anti-dsDNA antibody level. Furthermore, the IgG-binding data demonstrated that short DNA fragments (≤115 bp) were enriched in the IgG-bound fraction. Therefore, the data seem to suggest that there is preferential binding of anti-DNA antibody to short DNA fragments hindering the clearance of short DNA from the circulation.
Our previous data showed that plasma DNA of healthy individuals and pregnant women have a characteristic size profile with a prominent peak at 166 bp and a series of smaller peaks that are 10-bp apart (20) . This characteristic pattern was reminiscent of the length of DNA in a nucleosomal unit. We have also previously shown that the shorter plasma DNA molecules tend to be more hypomethylated than the longer molecules (29) . Hypomethylated DNA tended to be less densely packed with histones (40) and might be more susceptible to enzymatic degradation and provide more access to antibody binding. We therefore studied the methylation profile of DNA in the plasma of SLE patients. We found that plasma DNA of active SLE patients was generally hypomethylated compared with that of healthy individuals. The degree of hypomethylation correlated with the disease activity and the anti-dsDNA antibody level. The IgG binding experiment showed that the IgG-bound plasma DNA molecules were more hypomethylated (Fig. 7) . This observation suggests that some hypomethylated DNA molecules are retained in plasma of SLE patients because of antibody-binding. On the other hand, our data show that antibody-binding results in an enrichment of short plasma DNA fragments. These observations were therefore consistent with our finding that there was a relationship between the genome-wide methylation density and the size of plasma DNA in SLE patients, in which the shorter DNA fragments were more hypomethylated. This finding was also consistent with our previous study on circulating fetal DNA (29) .
Early studies have reported the phenomenon of DNA release from lymphocytes into serum (41, 42) . Interestingly, a number of recent studies have reported the hypomethylation of T cells in SLE patients (43, 44) . Hence, the release of DNA from hypomethylated cells, such as T cells, might be another mechanism that could contribute toward the hypomethylation of plasma DNA of SLE patients.
In summary, plasma DNA of SLE patients could exhibit aberrant MGRs, size shortening, and hypomethylation. These features might potentially be useful as biomarkers for SLE. Further studies with larger sample size, longitudinal specimen collections, and subgroup analysis of cases with specific clinical manifestations (e.g., renal involvement) may provide a more in-depth understanding of plasma DNA in SLE patients and its potential value for clinical practice. Our study also highlights the possibility that the study of plasma nucleic acids would be a valuable venue for research for other autoimmune diseases. (26) . Clinical information on the SLE patients is summarized in Dataset S2. Peripheral blood was collected in EDTA-containing tubes. The blood samples were first centrifuged at 1,600 × g for 10 min at 4°C and the plasma portion was further subjected to centrifugation at 16,000 × g for 10 min at 4°C to pellet the residual cells.
Separation of IgG-Bound and Unbound DNA in Plasma. The plasma samples were separated into the IgG-bound and non-IgG-bound fractions using the NAb Spin Column (Thermo Fisher Scientific), which contained an immobilized protein G resin for IgG protein capturing. The separation was performed according to the manufacturer's instructions, except for the following modifications for purifying the IgG-bound fraction. After the elution of the nonIgG-bound fraction, the NAb Spin Column was washed with PBS for six times.
To ensure a complete removal of the non-IgG-bound fraction before elution of the IgG-bound fraction, the final PBS wash was confirmed to have undetectable DNA level by using a real-time PCR quantification of the leptin (LEP) gene (45) . Then, the IgG-bound DNA remaining in the resin of the column was eluted with six washes of freshly prepared buffer containing 1% SDS and 0.1 M sodium bicarbonate.
DNA Extraction and Preparation of DNA Libraries. DNA was extracted from 4 to 10 mL of plasma using the DSP Blood Mini Kit (Qiagen) with modifications of the manufacturer's protocol as previously reported (38) . The concentrations of plasma DNA were determined by the real-time PCR assay of the LEP gene (45). Short DNA fragments of less than 62 bp can be underestimated with the use of this assay, as the amplicon size was 62 bp. For DNA sequencing, plasma DNA libraries were prepared using the Paired-End Sequencing Sample Preparation Kit (Illumina), as previously described (28) . For bisulfite sequencing, bisulfite-treated plasma DNA libraries were prepared using the Paired-End Sequencing Sample Preparation Kit (Illumina) and the EpiTect Plus DNA Bisulfite Kit (Qiagen) (29) .
DNA Sequencing and Alignment. The bisulfite-treated or untreated DNA libraries were sequenced for 75 bp of each end in a paired-end format on HiSeq2000 instruments (Illumina). DNA clusters were generated with a PairedEnd Cluster Generation Kit v3 on a cBot instrument (Illumina). Real-time image analysis and base calling were performed using the HiSeq Control Software v1. 4 and Real Time Analysis Software v1.13 (Illumina), by which the automated matrix and phasing calculations were based on the spiked-in PhiX control v3 sequenced with the libraries. After base calling, adapter sequences and lowquality bases (i.e., quality score < 5) on the fragment ends were removed. For the analysis of sequencing data, the sequenced reads were aligned to the nonrepeat-masked human reference genome (NCBI build 37/hg19) using the Short Oligonucleotide Alignment Program 2 (46) . Alignment was performed with the following settings: (i) two mismatches were allowed; (ii) alignment to multiple regions was not allowed; (iii) insertions or deletions compared with the reference genome were not analyzed; and (iv) DNA fragment size ranged from 20 to 600 bp.
Molecular Size Determination of Plasma DNA. Paired-end sequencing, where sequencing was performed for both ends of each DNA molecule, was used to analyze each sample. By aligning the pair of end sequences of each DNA molecule to the reference human genome and noting the genome coordinates of the extreme ends of the sequenced reads, the sizes of the sequenced DNA molecules were determined. Plasma DNA molecules are naturally fragmented and hence the sequencing libraries for plasma DNA are typically prepared without any fragmentation steps (28) . Hence, the lengths deduced by the sequencing represented the sizes of the original plasma DNA molecules.
Methylation Analysis of Plasma DNA. For the analysis of bisulfite-converted DNA sequencing data, an additional step for identification of methylated cytosines was performed. The trimmed reads were processed by a methylation data analysis pipeline called Methy-Pipe (47) . To align the bisulfiteconverted sequencing reads, we first performed in silico conversion of all cytosine residues to thymines, on the Watson and Crick strands separately, using the reference human genome (NCBI build 37/hg19). We then performed in silico conversion of each cytosine to thymine in all of the processed reads and kept the positional information of each converted residue. After that, Methy-Pipe was used to align the converted reads to the two preconverted reference human genomes, with a maximum of two mismatches allowed for each aligned read. The cytosines originally present on the sequenced reads were recovered based on the positional information kept during the in silico conversion. The recovered cytosines among the CpG dinucleotides were scored as methylated. Thymines among the CpG dinucleotides were scored as unmethylated. We determined the methylation density of the whole human genome or any particular regions in the genome by determining the total number of unconverted cytosines at CpG sites as a proportion of all CpG sites covered by sequence reads mapped to the genome or the particular regions in the genome.
Statistical Analysis. Analysis was performed by using in-house bioinformatics programs, which were written in Perl and R languages, and SigmaStat v3.5 software (Systat Software). A P value of less than 0.05 was considered as statistically significant and all probabilities were two-tailed. Fig. 7 . Percentage of significant DNA hypomethylation in plasma of SLE patients with high anti-dsDNA antibody levels (S124, S203, and S147). Red, blue, and green bars indicate the IgG-bound, neat, and non-IgG-bound fractions, respectively.
